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Abstract 
We report the case of a woman with diffuse brain metastases from lung cancer who 
experienced total regression of the metastases under gefitinib treatment. The 58-year-
old woman was referred to our hospital with a complaint of severe headache. A brain MRI 
revealed diffuse metastatic lesions in the cerebra and cerebellum. Adenocarcinoma of 
the lung with multiple brain metastases was diagnosed. The tumor was positive for an 
epidermal growth factor receptor (EGFR) exon 19 deletion mutation. She was treated 
with gefitinib 250 mg per day. One year later, the diffuse brain metastases had totally 
resolved. EGFR-tyrosine kinase inhibitor therapy could be a first-line treatment for 
patients with advanced adenocarcinoma of the lung with EGFR mutation, especially in 
those with brain metastases. 
 
Introduction 
Brain metastases are the most common type of intracranial neoplasm, and lung cancer 
is the most frequent neoplasm of brain metastases. Non-small cell lung carcinoma 
(NSCLC) has a 20–40% chance of developing brain metastases in the disease course [1]. Case Rep Oncol 2011;4:445–451 
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Whole-brain radiotherapy or platinum-based chemotherapy have been the standard 
therapy choices for patients with brain metastases, but the prognosis of patients with 
brain metastases is still disappointing. Penetration of chemotherapeutic drugs into the 
central nervous system (CNS) is limited primarily by the blood-brain barrier (BBB) [2]. 
Gefitinib is an oral agent and epidermal growth factor receptor (EGFR) tyrosine kinase 
inhibitor (TKI), which has been reported to be effective in the treatment of brain 
metastases from NSCLC by overcoming the BBB. An EGFR mutation is a predictive 
biomarker for a good response to EGFR-TKI, even in brain metastases [3]. 
Here, we report the case of a woman with diffuse brain metastases from lung cancer 
who experienced total regression of the metastases under gefitinib treatment. 
Case Report 
The patient, a 58-year-old married Taiwanese woman, was referred to our hospital with a complaint 
of severe headache and unsteady gait for 2 months. 
The patient had had a 10-year history of hypertension and a 4-year history of hyperthyroidism with 
regular follow-up. She denied cigarette smoking and alcohol consumption. Physical examinations 
revealed tenderness over her posterior neck and drowsy consciousness, with a Glasgow Coma Scale 
score of E2, V4, M4, and an ECOG performance status of grade 4. 
On admission, the patient underwent a brain MRI which revealed diffuse metastatic lesions of 
variable sizes in the cerebra and cerebellum (fig. 1a). A chest X-ray revealed a focal mass in the left 
infrahilar region, and a chest CT scan showed a lobulated mass, measuring 3.5 × 2.1 cm
2, in the superior 
segment of the left lower lobe (LLL) of the lung with pleural effusion (fig. 2a). The pathology of a 
transthoracic lung biopsy revealed adenocarcinoma. The Tc99M whole-body bone scan revealed 
multiple bone metastases. Therefore, adenocarcinoma of the LLL portion of the lung, with brain and 
bone metastases, cT2N3M1, stage IV was diagnosed. 
An analysis of the EGFR mutation elucidated a Glu746_Ala750 deletion in exon 19 (fig. 3). The 
patient received EGFR-TKI therapy with gefitinib 250 mg per day. Her subjective symptoms improved 
gradually within 1 month of gefitinib therapy. After 6 months of treatment, a chest CT scan revealed 
partial remission of the primary pulmonary tumor, measuring 3.0 × 1.5 cm
2 (fig. 2b). A brain MRI 
showed the dramatic total regression of the diffuse brain metastatic lesions (fig. 1b). Currently, the 
patient continues to receive EGFR-TKI therapy, and her survival time has exceeded 18 months since the 
initial diagnosis. So far, the patient has had a good ECOG performance status of grade 1 and no obvious 
recurrence elsewhere. 
Discussion 
NSCLC with brain metastases is usually associated with a poor outcome, and treatment 
is palliative in most cases. Multiple brain metastases are associated with an even worse 
prognosis, and median overall survival is only a few months. Standard treatment options 
include symptomatic therapy with whole-brain radiotherapy and corticosteroids, which 
lead to a median survival of 3–6 months [4]. 
The use of conventional chemotherapy for brain metastases has been limited because 
of a presumed lack of effectiveness due to poor penetration beyond the BBB. The BBB is a 
highly specialized structure of astrocytes, pericytes, and vascular endothelium that 
maintains CNS homeostasis. In a mouse model, the BBB has already been found to be 
permeable to brain metastases of tumors >0.25 mm in diameter. CT scans and MRI have Case Rep Oncol 2011;4:445–451 
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detected edema, and contrast enhancement in brain metastases has confirmed the 
disruption of the BBB, which is no longer intact when brain metastases become clinically 
detectable. Further studies show that EGFR-TKI has a low molecular weight and could 
penetrate beyond the BBB. Therefore, it might be efficacious in the treatment of brain 
metastasis [5, 6]. 
Many studies have proposed several factors which could make it possible to predict the 
response to gefitinib in patients with advanced NSCLC, for example, Asian female, non-
smoker, with adenocarcinoma, and the presence of an EGFR mutation. To our 
knowledge, the most common types of EGFR mutation are an exon 19 deletion and an 
exon 21 L858R mutation [7]. 
In our case, an Asian female had adenocarcinoma of the lung with diffuse brain 
metastases and was treated with gefitinib therapy because of an EGFR exon 19 deletion. 
After 6 months of follow-up, the dramatic response of total regression of the brain 
metastases was proved by brain MRI. As of now, our patient has survived more than 18 
months since the initial diagnosis. 
In conclusion, NSCLC patients with brain metastases usually have poor performance 
statuses. Chemotherapy has had limited effect in brain metastases. Therefore, due to its 
ability to reverse poor performance status and achieve the unbelievable response of total 
regression of brain metastases, EGFR-TKI therapy could be considered as a first-line 
treatment for advanced adenocarcinoma of the lung, positive for an EGFR mutation, with 
brain metastases. 
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Fig. 1. Chest response after 6 months of EGFR-TKI gefitinib therapy. CT scan showing a lobulated 
mass with pleural retraction in the superior segment of the LLL: before (a) and after (b) EGFR-TKI 
gefitinib therapy, with evident size reduction. 
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Fig. 2. Brain response after 6 months of EGFR-TKI gefitinib therapy. MRI showing diffuse metastasis of 
brain lesions: before (a) and after (b) EGFR-TKI therapy gefitinib, with total regression. 
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Fig. 3. PCR showing two bands for exon 19, denoting a small deletion in that exon. The lower band is 
the deleted product and the higher band is a heteroduplex of wild and deleted fragments. 
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